Target
histone deacetylase inhibitors (HDACi)
3 abstracts
Abstract
Synergistic cytotoxicity of histone deacetylase, poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: Therapeutic implications.Org: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shengjing Hospital of China Medical University, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, The First Affiliated Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
A randomized, open-label, phase II study of high-dose interleukin 2 vs high-dose interleukin 2 plus entinostat in renal cell carcinoma.Org: University at Buffalo Jacobs School of Medicine and Biomedical Sciences, USC Norris Comprehensive Cancer Center, Keck Medicine of USC, Nebraska Cancer Specialists - Midwest Cancer Center, Rush University Medical Center,